explore -WSS

explore

author：entertainment 2025-10-01 02:12:15 - browse：42126

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： FDA gives detailed accounting of AI

WSS

UnitedHealth’s board chair also owns a personal investment firm

Making AI in medicine accessible to smaller, and rural hospitals

Use wet bulb globe temperature, not heat index, to protect workers

Brain worms: The science behind RFK Jr.'s parasitic infection

Medicare says breakthrough device reimbursement rule to come by summer

H5N1 communication has been strictly for the birds

entertainment

explore

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Dairy farmers resist CDC push for PPE against bird flu virus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senate committee scrutinizes Medicare Advantage brokers

As demand for Covid shots wanes, Moderna seeks its next success

Study: Adult vaccinations pay for themselves in societal benefits

Hepatitis C has a cure — but many Americans still lack access to it

How to improve immunocompromised access to mAb treatments

In age of alternative facts, a scholarly course on calling out crap

What nurses really want: sufficient staffing for patient care

leisure time

The EU Joint Clinical Assessment needs to live up to its promise

Dairy farmers resist CDC push for PPE against bird flu virus

H5N1 bird flu: what we're starting to learn about infection in cows

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Google says AlphaFold 3 can map a vast universe of biomolecules

Use wet bulb globe temperature, not heat index, to protect workers

knowledge

hotspot

focus

hotspot